Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®

Core Insights - Halozyme Therapeutics has entered into a global collaboration and exclusive license agreement with Takeda for the use of its ENHANZE drug delivery technology with vedolizumab, marketed as ENTYVIO [1][2] - The collaboration aims to enhance patient experience by providing flexible treatment options for those with inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis [2][3] Company Overview - Halozyme is a biopharmaceutical company focused on innovative solutions to improve patient experiences and outcomes, particularly through its ENHANZE drug delivery technology, which utilizes the proprietary enzyme rHuPH20 [5] - The ENHANZE technology has been validated commercially, impacting over one million patients through ten products across more than 100 global markets [5] - Halozyme is also developing Hyperconâ™, a microparticle technology aimed at reducing injection volume while expanding the range of therapeutics that can be delivered subcutaneously [6] Industry Context - Crohn's disease and ulcerative colitis are significant forms of IBD, with an estimated 10 million people expected to be living with IBD globally within the next decade, indicating a growing healthcare burden [3] - Vedolizumab (ENTYVIO) is a biologic therapy approved for both intravenous and subcutaneous administration for adults with moderately to severely active IBD [4]